China Meheco Group (600056.SH): The subsidiary has received the approval notice for the listing application of Chemical Raw Materials.

Gelonghui reported on March 24 that China Meheco Group (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. (referred to as "Tianfang Pharmaceutical") has received a notification of approval for the marketing application of Febuxostat Chemical Raw Materials issued by the National Medical Products Administration. This pharmaceutical is suitable for the treatment of hyperuricemia in patients with gout. The approval of the marketing application for Febuxostat Chemical Raw Materials by Tianfang Pharmaceutical indicates that this Active Pharmaceutical Ingredient meets the relevant regulatory requirements for domestic drug registration and has been approved for use in domestic formulations. On one hand, it will achieve autonomous control of the company's Active Pharmaceutical Ingredient, and on the other hand, it indicates that this product can be.

Gelonghui FinanceMar 24 04:04 ET

Meheco Unit's Tranexamic Acid Injection Passes Regulatory Evaluation

MT NewswiresMar 10 23:24 ET

China Meheco Group (600056.SH): Tranexamic Acid Injection has passed the consistency evaluation for generic drugs.

On March 10, Gelonghui reported that China Meheco Group (600056.SH) announced that its wholly-owned subsidiary Tianfang Pharmaceutical Co., Ltd. had received an approval notice from the National Medical Products Administration for a supplementary application for tranexamic acid injection, which has passed the consistency evaluation of the quality and efficacy of generic drugs. Tranexamic acid injection is mainly used for various bleeding caused by acute or chronic, localized or systemic primary hyperfibrinolysis, which was originally developed by Daiichi Sankyo Company, Limited in Japan and was approved for market in Japan in 1965.

Gelonghui FinanceMar 10 05:22 ET

Meheco's Unit Gets Nod to Market Sacubitril-Valsartan Sodium Tablets

MT NewswiresMar 4 00:01 ET

The amount involved exceeds 0.5 billion yuan and the equity transfer dispute of China Meheco Group is still ongoing | Quick read of the announcement.

① China Meheco Group has appealed to the court regarding the acquisition of the remaining 30% equity in Jinlun Pharmaceutical (now named Hebei Tongyong) held by Wang Yibing; ② The amount involved in this lawsuit reaches 0.51 billion yuan.

cls.cnFeb 28 10:46 ET

[Brokerage Focus] CMB International indicates that China Meheco Group has started a valuation recovery.

Jinwu Financial News | China Merchants International states that the MSCI Chinese Medical Index has risen 5.3% year-to-date as of early 2025, outperforming the MSCI Chinese Index by 0.9%. Benefiting from overseas interest rate cuts and improvements in the domestic macro environment, the pharmaceutical sector, as a highly elastic industry, is expected to outperform the market in 2025. The Category C medical insurance directory is set to be implemented within the year, and Innovative Drugs will benefit from better payment conditions through commercial health insurance coverage. The bidding for Medical Devices is accelerating its recovery, which will drive the profit recovery of domestic medical device companies. The bank is Bullish about the recovery of industry valuations. It recommends buying WUXI APPTEC (02359, 603259 CH).

King Wu Financial NewsFeb 10 01:45 ET